Chinese commission reviewing drug pricing

China's National Development and Reform Commission (NDRC) is reviewing drug pricing and manufacturing costs for 60 Chinese and international pharmas. The commission said the review will take place between July and October and will look at 2010-12 data, including corporate audits, sales contracts and...